Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.
February 5, 2018

Tosk CEO Brian Frenzel meets with potential distribution partners and investors.

Brian Frenzel, CEO and co-founder of Tosk, recently returned from China , where he met potential distribution partners and investors.

“China obviously will be a key market for Tosk’s transformative cancer treatments,” Frenzel said. “We’ve had significant interest from pharmaceutical companies, especially now that we are in the midst of human trials. Investors, too, who have followed our progress, have accelerated their interest. We still have a portion of our Series D1 Preferred Stock offering at $6 per share available.”

Tosk is raising $5 million to complete proof of concept testing for TK-90, toxicity testing for TK-39 and preclinical testing for TK-kRAS and TK-88. TK-88 is intended to reduce or eliminate the adverse effects caused by such drugs as cisplatin and carboplatin.

“There are few if any companies of our size and focus that have four drugs at various stages of development,” according to Frenzel. “The market for our drugs will be huge, since treating common side effects of standard cancer drugs not only adversely affect the quality of life of patients and limit optimum dosing, but are extremely expensive to treat themselves.”